Zevra Therapeutics, Inc. (ZVRA)
(Delayed Data from NSDQ)
$8.49 USD
-0.04 (-0.47%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $8.50 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.49 USD
-0.04 (-0.47%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $8.50 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Zevra Stock Surges Close to 70% in 3 Months: Here's Why
by Zacks Equity Research
The FDA approval for ZVRA's Miplyffa (arimoclomol) capsules in September for treating Niemann-Pick disease type C drives the stock.
Biotech Stock Roundup: BHVN, WVE, ZVRA Stocks Up on Updates, BIIB & UCBs Study Data & More
by Zacks Equity Research
Biohaven and Zevra are in the spotlight following positive updates on key candidates.
Zevra Therapeutics (ZVRA) Moves 9.1% Higher: Will This Strength Last?
by Zacks Equity Research
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -2.13% and 8.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Journey Medical (DERM) delivered earnings and revenue surprises of -13.33% and 7.57%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Century Therapeutics (IPSC) delivered earnings and revenue surprises of 24% and 40.18%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
by Zacks Equity Research
Zevra Therapeutics (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
by Zacks Equity Research
The FDA will meet with its Genetic Metabolic Diseases Advisory Committee to review Zevra's (ZVRA) new drug application for pipeline candidate arimoclomol. Shares of Zevra gains on the news.
Zevra Therapeutics (ZVRA) Surges 21.9%: Is This an Indication of Further Gains?
by Zacks Equity Research
Zevra Therapeutics (ZVRA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of 18.37% and 2.70%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Esperion Therapeutics (ESPR) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 525% and 159.32%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
OptiNose (OPTN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Zevra Therapeutics (ZVRA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Zevra Therapeutics, Inc. (ZVRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alpine Immune Sciences, Inc. (ALPN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of 146.88% and 346.89%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Zevra Therapeutics (ZVRA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Strength Seen in Silence Therapeutics PLC Sponsored ADR (SLN): Can Its 15.4% Jump Turn into More Strength?
by Zacks Equity Research
Silence Therapeutics PLC Sponsored ADR (SLN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
How Much Upside is Left in Zevra Therapeutics (ZVRA)? Wall Street Analysts Think 248.51%
by Zacks Equity Research
The consensus price target hints at a 248.5% upside potential for Zevra Therapeutics (ZVRA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Acer (ACER) to Get Acquired by Zevra for $91M, Stock Up
by Zacks Equity Research
Acer (ACER) surges as Zevra Therapeutics offers to acquire it for approximately $91 million.
Can Zevra Therapeutics (ZVRA) Climb 227.55% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Zevra Therapeutics (ZVRA) points to a 227.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Sol-Gel Technologies Ltd. (SLGL) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sol-Gel Technologies Ltd. (SLGL) delivered earnings and revenue surprises of 15.38% and 61.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 32% and 7.35%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 9.72% and 29.72%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -30.77% and 3.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
OptiNose (OPTN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 15.01%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Cronos Group (CRON) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of 25% and 13.42%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?